Macquarie Group’s Tourmaline Bio TRML Stock Holding History

Macquarie Group’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,522	Closed	-$35	–	2141
2024 Q1	$35	Buy	+1,522	New	+$53.7K	﹤0.01%	1664

Other funds holding TRML

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Macquarie Group's TRML Position: Q2 2024 in Review

Macquarie Group sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 1,522 shares — an estimated $35 sold.

Macquarie Group first reported a position in TRML in Q1 2024 and held it in 1 quarter. The position peaked at $35 in Q1 2024. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

Macquarie Group reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 1,522 Tourmaline Bio shares in Q2 2024, an estimated $35.
Macquarie Group first reported a position in Tourmaline Bio in Q1 2024 and held it in 1 quarter.
Macquarie Group's Tourmaline Bio position peaked at $35 in Q1 2024.
84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.